HFrEF and Neurohormonal Systems
|
|
- Jonas Marshall
- 5 years ago
- Views:
Transcription
1 HFrEF and Neurohormonal Systems Normal Control of the Circulation: Neurohumoral Balance Vasoconstrictor Salt and H 2 O retaining Vasodilator Diuretic Richard Troughton CSANZ Breakfast Symposium 15 June 218 Endothelin Angiotensin II Norepinephrine Urocortin Neurohormonal Imbalance in Heart Failure Sympathetic Nervous System: Role in the pathophysiology of HF Excess vasodilation Compensation Excess vasoconstriction Endothelin Angiotensin II Vasopressin Norepinephrine Urocortin HF is characterized by heightened sympathetic tone Imbalances in baroreceptor reflexes and AngIIdependent SNS activation play an important role in adverse haemodynamic and cardiac responses Stimulation of SNS in HF results in Heart rate Contractility Na reabsorption Renal and peripheral vascular resistance Direct myocardial toxicity Adapted from Shah M et al. Rev Cardiovasc Med. 21;2(suppl 2):S2 S6. Ach=acetylcholine; AngII= angiotensin II; CV=cardiovascular; E=epinephrine; HF=heart failure; NE=norepinephrine; SNS=sympathetic nervous system Floras, JACC, 29, 34: Lymperopoulos et al. Circ Res 213;113:
2 RAAS: Initially compensatory and subsequently pathological in HF Landmark trials in HFrEF Angiotensinogen Renin Ang I ACEIs ACE ARBs AT 1 receptor Direct renin s CHARM-Alternative 3 (23) SOLVD-T 1 (1991) 2,28 patients 2,569 patients Candesartan (ARB) vs Enalapril (ACEI) vs 16% all-cause mortality 23% CV mortality or HF CIBIS-II 8 (1999) 2,647 patients Bisoprolol (BB) vs 34% all-cause mortality SHIFT 5 (21) 6,558 patients Ivabradine (I f ) vs 18% CV death or HF Signalling cascade 199s 2s 21s Biological actions hypertrophy secretion MRAs Na + /H 2O retention ADH Secretion Norepinephrine release Sympathetic tone MERIT-HF 2 (1999) 3991 patients Metoprolol vs 34% all-cause mortality CHARM-Added 4 (23) 2,548 patients Candesartan (ARB) vs 15% CV mortality or HF EMPHASIS-HF 6 (211) 2,737 patients Eplerenone (MRA) vs 37% CV mortality or HF Cardiac remodeling Myocyte necrosis Blood Pressure Blood volume Heart rate Contractility Studies ongoing; not approved for treatment of HF Zaman et al. Nat Rev Drug Discov 22;1:621 36; Schrier and Abraham. N Engl J Med 1999;341:577 85; Brewster et al. Am J Med ACE=angiotensin-converting enzyme; ACEI=angiotensin-converting-enzyme ; Sci 23;326:15 24; Schmieder. Am J Hypertens 25;18:72 3; McMurray et al. Eur Heart J 212;33: Francis et al. ADH=antidiuretic hormone; ARB=angiotensin receptor blocker; MRA=mineralocorticoid receptor Ann Intern Med 1984;11:37 7; antagonist; RAAS=renin-angiotensin-aldosterone system Von Lueder et al. Circ Heart Fail 213;6: ACEI=angiotensin-converting enzyme ; ARB=angiotensin receptor blocker; ARNI=angiotensin receptor neprilysin ; BB=beta blocker; CV=cardiovascular; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; MRA=mineralocorticoid receptor antagonist. See notes for definitions of study names 1. SOLVD Investigators. N Engl J Med 1991;325: MERIT-HF study group, Lancet, 1999, 353: Granger et al. Lancet 23;362: McMurray et al. Lancet 23;362: ; 5. Swedberg et al. Lancet 21;376: Zannad et al. N Engl J Med 211;364:11 21; 7. McMurray et al. N Engl J Med 214;371: CIBIS-II Investigators. Lancet 1999;353:9 13 Combination ACEI, -Blocker and MRA are now the cornerstone of therapy for HFrEF Neurohormonal Imbalance in Heart Failure ACEI +BB + MRA.44 (.26,.66) ACEI + ARB +BB.52 (.31,.8) ACEI +MRA.57 (.35,.91) ARB + BB.47 (.23,.86) ACEI + ARB.83 (.51, 1.24) ACEI + BB.57 (.41,.72) BB.57 (.33,.94) ARB.88 (.61, 1.26) ACEI.83 (.66, 1.1) HR (95% credible interval) for treatment vs. placebo HR<1 favors treatment Results are based on random-effects network meta-analysis using Bayesian models 2 Studies included: 57 RCTs, Phase II/III (Jan April 215) assessing guideline-recommended drug classes for HFrEF Excess vasodilation Compensation Excess vasoconstriction Endothelin Angiotensin II Vasopressin Norepinephrine Urocortin Patient population: Patients (aged 18 years) with chronic HFrEF (LVEF <45%) and NYHA class II IV of varying etiology presenting in the outpatient department were included 1. McMurray et al. Eur Heart J 212;33: ;.2. Burnett H et al. Circ Heart Fail. 217;1:e3529 Adapted from Shah M et al. Rev Cardiovasc Med. 21;2(suppl 2):S2 S6. 2
3 The Natriuretic Peptide Family Effects of the Natriuretic Peptides Cardiomyocytes 1 Endothelial cells 1 and H 2 N NPR-A NPR-B NPR-C H 2 N H 2 N Internalization Receptor recycling HOOC Vasodilation 1,2 HOOC HOOC Antihypertrophy 1,2 Antiproliferation 2 Vascular regeneration 3 Myocardial relaxation 4,5 Diuresis, natriuresis 1,2 Antiapoptosis 6 Anti-aldosterone 1,2 Vasodilation 1,2 Degradation Antihypertrophy 1,2 of NPs 7 Antiproliferation 2 Vascular regeneration 1 Venodilation 1 Natriuretic peptide Antifibrosis 1 degradation and clearance Renin secretion inhibition 7 Reduced sympathetic tone 8 Lipolysis 7 Courtesy of Dr Ruskoaho 1. Mangiafico et al. Eur Heart J 213;34:886 93; 2. Gardner et al. Hypertension 27;49:419 26; 3. Yamahara et al., PNAS, 23, 1: Yamamoto et al.,ajp, 1997, 273: H Clarkson et al., Clin Science 1995: 88: Kasama et al., Eur. Heart. J. 28: 29: Volpe et al., Clin Science, 216: 13: Levin et al. N Engl J Med 1998;339; Effect of Short Term Augmentation of and Levels in HFrEF. Natriuretic peptides are cleared via NPR-C and degraded by the protease, neprilysin Short term NP infusion not associated with improvements in mortality or hospitalisation NPR-A Cardiomyocytes 1 and NPR-B Endothelial cells 1 NPR-C NEP cleavage products Longer term infusion or S/C treatment not feasible Receptor recycling Endocytosis Inhibition of Clearance a potential therapeutic target Vasodilation 1,2 Antihypertrophy 1,2 Antiproliferation 2 Vascular regeneration 3 Myocardial relaxation 4,5 Diuresis, natriuresis 1,2 Antiapoptosis 6 Anti-aldosterone 1,2 Renin secretion inhibition 7 Vasodilation 1,2 Antihypertrophy 1,2 Antiproliferation 2 Vascular regeneration 1 Venodilation 1 Antifibrosis 1 Inactivation of NPs 7 Natriuretic peptide degradation and clearance Reduced sympathetic tone 8 Lipolysis 7 Lainchbury et al. Hypertension. 1999;34:7-75 Natriuretic peptide signaling and effects =atrial natriuretic peptide; =B-type natriuretic peptide; =C-type natriuretic peptide; =cyclic guanosine monophosphate; =guanosine triphosphate; NPR=neprilysin receptor 1. Mangiafico et al. Eur Heart J 213;34:886 93; 2. Gardner et al. Hypertension 27;49:419 26; 3. Yamahara et al., PNAS, 23, 1: Yamamoto et al.,ajp, 1997, 273: H Clarkson et al., Clin Science 1995: 88: Kasama et al., Eur. Heart. J. 28: 29: Volpe et al., Clin Science, 216: 13: Levin et al. N Engl J Med 1998;339;321 8;. 3
4 Plasma (pmol/l) Plasma (pmol/l) / Neutral Endopeptidase Cleavage Sites NEP is 749-AA, membrane-bound, zinc-dependent endopeptidase Found in epithelia, fibroblasts and neutrophils and in soluble form in the circulation, urine and CSF Widely present in kidneys, heart, brain, gut and lungs Antoni Bayes-Genis et al. JACC 216;68: and are degraded by neprilysin with similar levels of enzymatic efficiency is also degraded by neprilysin, but at a slower rate than and Antoni Bayes-Genis et al. JACC 216;68: Short-term NEP Inhibition in HFrEF Oral NEP inhibition elevates NP levels in patients with HF Candoxatril - an orally active of neprilysin Single oral doses of candoxatril increase and levels in seven patients with chronic HF 1# Before treatment After treatment mg 1 mg 5 mg 2 mg Dose of candoxatril mg 1 mg 5 mg 2 mg Dose of candoxatril # Seven patients (mean age 65) with chronic HF NYHA II III were given candoxatril 1, 5, 2 mg or placebo as a single dose in a four-way crossover study. Values as mean and SEM; p< 5 vs mg (placebo) (ANOVA); Lainchbury et al, J Clin Endocrinol Metab. 1999;84(2): 1. Lang et al. Lancet 1991;338:255 4
5 Proportion with event Proportion with event Oral NEP monotherapy failed to demonstrate clinical efficacy in HFrEF 1 Rationale for lack of efficacy with NEP monotherapy in HFrEF 1 Candoxatril showed minimal hemodynamic effects compared with placebo in patients with HFrEF 1-3 Left and right atrial pressures (reduced) Arterial pressures (no change) Heart rate (no change) Systemic or pulmonary vascular resistance (no change) Cardiac index (no change after exercise) Another neprilysin, ecadotril, led to numerically more deaths, as well as no evidence of clinical efficacy compared with placebo in patients with HF 2 Consequently, the development of both candoxatril and ecadotril for HF was discontinued 2 opposing actions of multiple neprilysin substrates increased levels offsetting beneficial effects of enhancing the NP system systemic vasoconstrictor rather than vasodilator effects (in part due to increased levels of the potent vasconstrictor ET-1) Natriuretic peptides Angiotensin II Angiotensin I Substance P Bradykinin Endothelin NEP fragments or metabolites Westheim et al. J Am Coll Cardiol 1999;34: ; 2. Cleland and Swedberg. Lancet 1998; 351: MaDowell and Nicholls, Cardiovasscular drug reviews, 2; 18: Westheim et al. J Am Coll Cardiol 1999;34: ; 2. Kimmelstiel et al. Cardiology 1996;87:46 53; 3. Kentsch et al. Eur J Clin Pharmacol 1996;51:269 72; 4. McDowell et al. Br J Clin Pharmacol 1997;43:329 32; 5. Ando et al. Hypertension 1995;26:116 6; 6. Von Lueder et al. Pharmacol Ther 214;144: 41 9; 7. Langenickel and Dole. Drug Discov Today:Ther Strateg 212;9:e inhibition must be accompanied by simultaneous RAAS blockade Angiotensinogen metabolizes Ang I and 1,2 Inhibition of neprilysin alone is associated with an increase in levels, counteracting the potential benefits of neprilysin inhibition 2 inhibition must be accompanied by simultaneous RAAS blockade Ang I Renin ACE AT 1 receptor Ang-(1 7) fragments Vasopeptidase s (dual NEP and ACE inhibition) showed promise in HFrEF The IMPRESS study, tested the efficacy and safety of omapatrilat compared with the ACEi lisinopril in 573 patients with HFrEF over 24 weeks.15 Death or admission for heart failure.15 Death, admission for heart failure, or discontinuation of treatment Signaling cascade.1 Lisinopril Omapatrilat p=.52.1 Lisinopril Omapatrilat p=.35 Biological actions.5.5 Na + /H 2O retention Norepinephrine release release Sympathetic tone 1. Von Lueder et al. Circ Heart Fail 213;6:594 65; 2. Langenickel and Dole. Drug Discov Today: Ther Strateg 212;9:e Time from randomization (days) Time from randomization (days) A randomized, double-blind, parallel trial in patients with chronic HF NYHA class II IV, LVEF 4%, and receiving an ACEI. Omapatrilat 4 mg (n=289) or lisinopril 2 mg (n=284) 1. Rouleau et al. Lancet 2;356:
6 Event-free survival (%) OVERTURE study showed trends towards efficacy with dual NEPi/ACEi but raised significant safety concerns Omapatrilat was compared with enalapril in 5,77 patients with HFrEF Time to death or HF 3 Omapatrilat Enalapril Months p= Omapatrilat discontinued due to: Lack of efficacy attributed to sub-optimal neprilysin and ACE inhibition over 24 hours due to the once-daily dosing regimen Safety concern unacceptable risk of angioedema (24 patients [.8%] vs 14 patients [.5%] for omapatrilat and enalapril, respectively)., attributed to dual neprilysin and ACE inhibition leading to elevated bradykinin levels, Co-inhibition of neprilysin and AT1-receptor: better efficacy with lower angioedema risk? Bradykinin is a substrate of neprilysin, ACE and other vasopeptidases Simultaneous inhibition of ACE and neprilysin results in elevated levels of bradykinin leading to higher risk of cough and angioedema 1,2 A selective neprilysin coupled with an ARB can enhance beneficial effects of NP system while inhibiting RAAS with minimal effect on bradykinin degradation 1 Omapatrilat inhibits ACE, APP and NEP 2 Selective NEP and ARB inhibition Active bradykinin Active bradykinin Bradykinin breakdown ACE APP NEP DPP-4 bradykinin bradykinin Packer et al.circulation 22;16: McMurray et al. Eur J Heart Fail 214;16:817 25; 2. Gu et al. J Clin Pharmacol 21;5: 41 14; Sacubitril/Valsartan a first in class dual neprilysin and AT1 receptor blocker Sacubitril/Valsartan is a salt complex comprised of two active components in a 1:1 molar ratio sacubitril (AHU377) a pro-drug metabolised to the neprilysin sacubitrilat valsartan an AT1 receptor blocker 3D sacubitril/valsartan structure 2 1. Bloch and Basile. J Clin Hypertens 21;12:89 12; 2. Gu et al. J Clin Pharmacol 21;5:41 14; 3. Langenickel and Dole. Drug Discov Today: Ther Strateg 212;9:e
7 Landmark trials in HFrEF CHARM-Alternative 3 (23) SOLVD-T 1 (1991) 2,28 patients 2,569 patients Candesartan (ARB) vs Enalapril (ACEI) vs 16% all-cause mortality 23% CV mortality or HF CIBIS-II 8 (1999) 2,647 patients Bisoprolol (BB) vs 34% all-cause mortality SHIFT 5 (21) 6,558 patients Isvabradine (I f ) vs 18% CV death or HF PARADIGM-HF 7 (214) 8,442 patients Sacubitril/valsartan (ARNI) vs enalapril: 199s 2s 21s MERIT-HF 2 (1999) 3991 patients Metorprolol vs 34% all-cause mortality CHARM-Added 4 (23) 2,548 patients Candesartan (ARB) vs 15% CV mortality or HF EMPHASIS-HF 6 (211) 2,737 patients Eplerenone (MRA) vs 37% CV mortality or HF ACEI=angiotensin-converting enzyme ; ARB=angiotensin receptor blocker; ARNI=angiotensin receptor neprilysin ; BB=beta blocker; CV=cardiovascular; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; MRA=mineralocorticoid receptor antagonist. See notes for definitions of study names 1. SOLVD Investigators. N Engl J Med 1991;325: MERIT-HF study group, Lancet, 1999, 353: Granger et al. Lancet 23;362: McMurray et al. Lancet 23;362: ; 5. Swedberg et al. Lancet 21;376: Zannad et al. N Engl J Med 211;364:11 21; 7. McMurray et al. N Engl J Med 214;371: CIBIS-II Investigators. Lancet 1999;353:9 13 Sacubitril/valsartan development timelines in HFrEF Through its action of hydrolysis, NEP inhibition leads to natriuresis and diuresis First in class oral dual NEP and ACE s discovered but discontinued due to significant angioedema cases Largest HF trial in history compares sacubitril/valsartan to ACEi enalapril in HFrEF patients Sacubitril/valsartan (Entresto ) receives Australian TGA approval and is listed on the ARTG : NEP research : Omapatrilat and Angioedema : PARADIGM-HF study. Trial stopped early 2 Jan 216 TGA Approval The future : is discovered 25-26: Sacubitril/ valsartan is born 215: Sacubitril/ valsartan approval in US and EU 1 June 217 PBS Listing released by heart under stress conditions lowers the blood pressure Novartis develops a unique, well-defined crystalline salt complex comprising valsartan and sacubitrilat along with sodium ions and water. A proof of concept human study of sacubitril/valsartan in hypertension gives positive results Both ESC-HF and US guidelines give a recommendation of class IB and replacement of ACEi/ARB with sacubitril/valsartan in all symptomatic HFrEF patients Sacubitril/ valsartan is available on the PBS 1. de Bold AJ et al. Life Sci 1981;28:89 94; 2. Brauwald E et al, J Am Coll Cardiol 215;65:
8 Sacubitril/valsartan: inhibition combined with RAAS blockade is an alternative to an ACEI or ARB in patients with HFrEF 1 s NPRs NPs Vasodilation Blood pressure Sympathetic tone Natriuresis/diuresis Vasopressin INACTIVE FRAGMENTS NP system HF SYMPTOMS & PROGRESSION Sacubitril/valsartan SNS Epinephrine α 1, β 1, β 2 Norepinephrine receptors RAAS activity Vasopressin Heart rate Contractility RAAS AT 1R Blood pressure Sympathetic tone β-blockers RAAS s (ACEI, ARB, MRA) ACEI=angiotensin-converting enzyme ; Ang=angiotensin; ARB=angiotensin receptor blocker; AT 1R=angiotensin II type 1 receptor; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; MRA=mineralocorticoid receptor antagonist; NP=natriuretic peptide; NPRs=natriuretic peptide receptors; RAAS=renin-angiotensin-aldosterone system; SNS=sympathetic nervous system 1. McMurray et al. Eur J Heart Fail 213;15:162 73; 2. Minguet et al., Exp. Opin.Pharamacother, 215, 16:435-46;, Figure references: Levin et al. N Engl J Med 1998;339:321 8 degrades other vasoactive peptides substrates including NPR-A NPR-B NPR-C Ang I Bradykinin ET-1 Substance P cleavage products AT 1 receptor inhibition must be accompanied by simultaneous RAAS blockade Angiotensinogen metabolizes Ang I and 1,2 Inhibition of neprilysin alone is associated with an increase in Ang II levels, counteracting the potential benefits of neprilysin inhibition 2 inhibition must be accompanied by simultaneous RAAS blockade Ang I Renin ACE AT 1 receptor Ang-(1 7) fragments Endocytosis Inactivation of NPs 1,2,5 Receptor recycling Signaling cascades Biological actions Signaling cascade Vasodilation Cardiac fibrosis/hypertrophy Natriuresis/diuresis Cardiac fibrosis/hypertrophy Sodium/water retention Na + /H 2O retention release Norepinephrine release Sympathetic tone 1. Von Lueder et al. Circ Heart Fail 213;6:594 65; 2. Langenickel and Dole. Drug Discov Today: Ther Strateg 212;9:e
9 9
Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationMEDICAL THERAPY IN HEART FAILURE
MEDICAL THERAPY IN HEART FAILURE Dr Lim Choon Pin MBBS, MRCP (UK), MMed (Int Med), FAMS, FESC, FACC Consultant Cardiologist, The Heart and Vascular Centre Heart Failure, Heart Transplant, Mechanical Circulatory
More informationLCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO. Dario Leosco Università di Napoli Federico II
LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO Dario Leosco Università di Napoli Federico II Projected changes in cardiovascular diseases CVD Deaths Increase 33% CVD DALYS 22% CAD
More informationUNMET NEEDS IN THE MANAGEMENT OF HEART FAILURE
UNMET NEEDS IN THE MANAGEMENT OF HEART FAILURE By Mohammed Sadaka, MD ALEXANDRIA UNIVERSITY 2 Presentation Title Presenter Name Date Subject Business Use Only 1 HF is a complex syndrome involving multiple
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationRAAS blocker + B Blocker Troubleshooting
RAAS blocker + B Blocker Troubleshooting Heart Failure ECHO Clinic Virtual Heart Failure Consultation and Education Prof Ken McDonald & Dr. Patricia Campbell 13 th March 2017 HF activates 3 neurohormonal
More informationNeurohormonal blockade: is there still room to go?
Neurohormonal blockade: is there still room to go? M.Birhan YILMAZ, MD, FESC, FACC, FHFA Professor of Cardiology, Cumhuriyet University Sivas, TURKEY President of Heart FailureWG of Turkish Society of
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationECG in CRT patients & novel HF therapies. Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος
ECG in CRT patients & novel HF therapies Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received grants from Medtronic Is identification
More informationSessions Formació Continuada en Cardiologia i Especialitats Relacionades Cardioactualitat: Noves estratègies terapèutiques en el maneig de la IC
Sessions Formació Continuada en Cardiologia i Especialitats Relacionades Cardioactualitat: Noves estratègies terapèutiques en el maneig de la IC J. Comin Colet Cap de Secció del Servei de Cardiologia i
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationDoes My Patient Always Require Diuretics???
Does My Patient Always Require Diuretics??? Shelley Zieroth, MD Associate Professor, Section of Cardiology Director, SBH Heart Failure and Transplant Clinics Head, Medical Heart Failure Program WRHA Cardiac
More informationImproving outcomes in heart failure with reduced EF
Improving outcomes in heart failure with reduced EF Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationL insuffisance cardiaque chez la personne âgée
L insuffisance cardiaque chez la personne âgée Congrès d automne de la SSMIG Berne, 14.09.2017 Prof. Dr. Jean-Michel Gaspoz Département de Médecine communautaire, de premier recours et des urgences Conflicts
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationHF TREATMENT PROGRESS
Mortality Digoxin, Diuretics, Hydralazi ne HF TREATMENT PROGRESS SOLVD CONCENSUS -16 to -31 % + ACE-I CIBIS II COPERNICUS -35 % + b- blockers RALES -22 % COMPANION & CARE HF -36 % + Aldostero ne Inhibitors
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationAndy Ignaszewski MD FRCPC Director, Heart Function Clinic PHC/UBC Vancouver, BC Canada
Andy Ignaszewski MD FRCPC Director, Heart Function Clinic PHC/UBC Vancouver, BC Canada Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationOptimal Management of Heart Failure
Curriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine Faculty of Medicine UI Medical Student : Faculty of Medicine
More informationCritical Challenges of Acute Heart Failure
Critical Challenges of Acute Heart Failure Jonathan Howlett, MD, FRCPC, FACC Libin Cardiovascular Institute and University of Calgary President, Canadian Heart Failure Society Presenter Disclosure Faculty/Presenter:
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationHeart Failure. Optimising treatment and balancing co-morbidity in the community. Andrew Ludman Cardiologist
Heart Failure Optimising treatment and balancing co-morbidity in the community Andrew Ludman Cardiologist What is heart failure? A structural cardiac abnormality leading to failure of the heart to provide
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationTerapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice
Terapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice Cattedra di Cardiologia Seconda Università di Napoli 60 CONGRESSO NAZIONALE SIGG NAPOLI, 25-28 NOVEMBRE
More informationNew Pharmacological Developments In Heart Failure
New Pharmacological Developments In Heart Failure Diego Delgado, MD, FACC, MSc Associate Professor Site Director, Division of Cardiology Toronto General Hospital Heart Failure and Transplant Program University
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationHeFSSA Prac++oners Program 2016 What is NEW in Heart Failure treatment?
HeFSSA Prac++oners Program 2016 What is NEW in Heart Failure treatment? 08:00 Registra-on 08:25 Welcome and Thank You to Sponsors 08:30 09:15 10:00 10:30 The new kid on the block ARNI How do I effec-vely
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationA new class of drugs for systolic heart failure: The PARADIGM-HF study
INTERPRETING KEY TRIALS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will describe the mechanism and use of angiotensin receptor-neprilysin inhibitors in heart failure MARWA A. SABE, MD, MPH Department of
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationΝέες θεραπευτικές προσεγγίσεις για τους ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξωθήσεως (HFrEF).
Νέες θεραπευτικές προσεγγίσεις για τους ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξωθήσεως (HFrEF). ΧΑΡΑΛΑΜΠΟΣ Ι. ΚΑΡΒΟΥΝΗΣ Καθηγητής Καρδιολογίας Α.Π.Θ. Disclosures Teaching grants and honoraria
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationChronic Heart Failure. Dr Eric Klug Heart Failure Clinic: CM Johannesburg Academic Hospital. Sunninghill and Sunward Park Hospitals
Chronic Heart Failure Dr Eric Klug Heart Failure Clinic: CM Johannesburg Academic Hospital. Sunninghill and Sunward Park Hospitals The most important slide: The challenge of chronic The good physician
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationThe Management of Heart Failure A PARADIGM Shift?
The Management of Heart Failure A PARADIGM Shift? Richard Clarens, PharmD UND School of Medicine & Health Sciences Altru Family Medicine Residency NDSU College of Pharmacy, Nursing, & Allied Sciences OBJECTIVES
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationSacubitril/valsartan: a cardiovascular drug with pluripotential actions
Editorial Sacubitril/valsartan: a cardiovascular drug with pluripotential actions Steven G. Chrysant 1, George S. Chrysant 2 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2 INTEGRIS
More informationHeart Failure is the Fastest Rising Cardiovascular Condition in Canada. HF is a Progressive Condition with High Morbidity and.
Function & quality of life (QoL) Approved HF agents 1.Management of Heart Failure Patients in Ontario: Recommendations from Best Practice, April 213, *Ross et al. Treating the right patient at the right
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationDr Dinna Soon. Consultant Cardiologist, Department of Cardiology. GP symposium 2 April 2016
Dr Dinna Soon Consultant Cardiologist, Department of Cardiology GP symposium 2 April 2016 Case presentation 76 years old male, chronic smoker, hypertension, previous MI 3/7 SOB and chest tightness BP
More informationDual blockade angiotensin-receptor neprilysin-inihibitor (ARNI) - A new era for heart failure treatment
OF JOURNAL HYPERTENSION JH R RESEARCH Journal of HYPERTENSION RESEARCH www.hypertens.org/jhr Review Dual blockade angiotensin-receptor neprilysin-inihibitor (ARNI) - A new era for heart failure treatment
More informationREVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2
Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 1 University of Missouri School of Medicine, Columbia, MO 2 Division of Cardiovascular Medicine, Department
More informationFeast after Famine: The New Drugs for the Treatment of Heart Failure
Feast after Famine: The New Drugs for the Treatment of Heart Failure Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A., F.E.S.C. Medical Director, Advocate Medical Group-Midwest Heart Specialists Heart Failure
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationHow Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More information2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline
Advances in the Use of Biomarkers in Heart Failure Patients Lori B. Daniels, MD, MAS, FACC, FAHA Professor of Medicine Director, Cardiovascular Intensive Care Unit Sulpizio Cardiovascular Center UC San
More informationBehandeling van Hartfalen: over 5 jaar
Behandeling van Hartfalen: over 5 jaar Adriaan Voors, cardioloog UMCG Over 5 jaar Heart Failure Treatment in 5 Years HFrEF: best evidence, biggest pipeline Entresto Omcamtiv LVAD: destination therapy HFrEF:
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than cancer
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 8 6 4 2 3.5 4.8 1. 1991 21 237 US prevalence*: 5.8 million US annual incidence: 67, Annual mortality: 282,754 5-1% depending on severity
More informationChronic Heart Failure Therapies: Transforming the Landscape
Chronic Heart Failure Therapies: Transforming the Landscape Dr. Nadia Giannetti Chief of Cardiology Medical Director, Heart Failure and Heart Transplant Program McGill University Health Center Conflict
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationPre-discussion questions
Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHeart Failure Update. Chim Lang
Heart Failure Update Chim Lang Heart Failure Patient s Journey Acute Treat and stabilize Initiate monitoring Plan interventions Chronic Optimize drug and device therapy Manage Co-morbidities Subacute
More informationTHE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM The renin angiotensin system (RAS) or the renin angiotensin aldosterone system (RAAS) is a hormone system that is involved in the regulation of the plasma sodium
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationHeart Failure Pharmacotherapy An Update
Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF
More informationLearning Objectives. Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis
7:5 :5 am Update in Heart Failure SPEAKER Orly Vardeny, PharmD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Orly Vardeny, PharmD, MS: Advisory Board
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationOTE HAR M A. Sacubitril/Valsartan (Entresto ): A New Dual Therapy Approved For Chronic Heart Failure. Vol. 31, Issue 3 December 2015.
P HAR M A Vol. 31, Issue 3 December 2015 N OTE Established 1985 Sacubitril/Valsartan (Entresto ): A New Dual Therapy Approved For Chronic Heart Failure Kellen Danley, PharmD Candidate H eart Failure (HF)
More informationMayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi
334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More information